AI Data Insight
In the second quarter of 2026, US imports of medical, dental, and pharmaceutical products reached 45.767 billion USD, significantly rebounding by 18.6% from 38.563 billion USD in the previous quarter. As the US government implemented high tariffs on patented drugs under "Section 232", pharmaceutical companies accelerated their stockpiling ahead of the deadline and actively adjusted their supply chains to seek exemptions. Looking ahead, the full implementation of high tariffs will drive up industry costs and accelerate the reshoring of the medical supply chain back to the US.